Adaptimmune Therapeutics PLC Sponsored ADR
(NASDAQ : ADAP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.44%72.430.9%$622.43m
CELGCelgene Corporation
0.29%128.021.1%$446.62m
AMGNAmgen Inc.
0.39%167.941.1%$420.10m
BIIBBiogen Inc.
0.30%282.621.2%$357.46m
REGNRegeneron Pharmaceuticals, Inc.
0.55%470.562.7%$323.60m
VRTXVertex Pharmaceuticals Incorporated
0.70%149.171.9%$266.46m
ALXNAlexion Pharmaceuticals, Inc.
1.15%134.931.9%$220.47m
ILMNIllumina, Inc.
0.35%189.993.5%$217.12m
SRPTSarepta Therapeutics, Inc.
0.38%36.8419.8%$138.97m
INCYIncyte Corporation
-1.00%119.982.6%$129.64m
CLVSClovis Oncology, Inc.
0.21%72.1118.0%$129.47m
KITEKite Pharma, Inc.
1.60%132.2616.1%$123.79m
TSROTESARO, Inc.
0.69%114.6514.7%$122.53m
AAgilent Technologies, Inc.
0.49%61.551.5%$119.61m
BMRNBioMarin Pharmaceutical Inc.
0.30%81.164.4%$108.90m

Company Profile

Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.